Trial Profile
A Randomized Phase II/III Trial of SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron) vs. INTRON®A as Adjuvant Therapy for Melanoma
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 19 Jun 2018 New trial record